Abstract Background: Today, degenerative aortic valve stenosis, also called aortic stenosis (AS), is the most prevalent disease of the heart valves in the Western world, and the prevalence is expected to increase with the aging population. The introduction of TAVI (transcatheter aortic valve implantation) was introduced in 2002. It has changed the management of AS fundamentally. TAVI has been established as the preferred therapeutic option for patients with severe AS who are inoperable or has a high surgical risk. Objective: The aim of the study is to give an overview on the development of TAVI, its implementation as a therapy of patients with AS, and present how the procedure has changed the indications and prognosis for this group of patients. Methods: We conducted a non-systematic search in literature in databases, registries, guidelines and books. This was supplemented with interviews with cardiologists and thoracic surgeons. Results: The search resulted in the use of 48 articles and 11 studies. Studies has shown that TAVI is non-inferior to SAVR in intermediate-risk patients. Various limitations of TAVI where found, like valve durability and function, paravalvular leak, interference in the conducting system, and differences in morbidity and mortality. Conclusions: This literature search indicates the use of TAVI in high-risk patients is supported by robust data from multiple randomized clinical trials. Ongoing trials will hopefully provide important information of the use of TAVI in intermediate-risk-, low-risk- and younger patients, and in patients with bicuspid AS. Literature indicates that we are moving in a direction of broader indications for the use of TAVI as therapy of AS.